Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences Inc. NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.

Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...

Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold shares of the company's common stock. According to a recent SEC filing, Roberts sold 1,457 shares on January 31 at an average price ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a look at where Neurocrine Biosciences, Inc.